Tiziana Life Sciences
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 9
- Market Cap
- $125.8M
- Introduction
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
- Conditions
- Non-Active Secondary Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 55
- Registration Number
- NCT06890923
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
- Conditions
- SafetyTolerability
- Interventions
- Drug: Foralumab NasalDrug: Placebo
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 27
- Registration Number
- NCT06879067
- Locations
- 🇺🇸
Ann Romney Center for Neurologic Diseases, Boston, Massachusetts, United States
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
- Conditions
- Multiple System Atrophy
- Interventions
- Drug: Foralumab Nasal
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 5
- Registration Number
- NCT06868628
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
- Conditions
- Non-Active Secondary Progressive Multiple Sclerosis
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT06802328
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 54
- Registration Number
- NCT06292923
- Locations
- 🇺🇸
Yale, North Haven, Connecticut, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- Next